Revenue $10.05B, up 9.5% on a year earlier. Other revenues $517.00M, up 26.7%. Product sales $9.54B, up 8.7%. Diluted EPS $4.37 against $2.65.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $10.05B | $8.62B | $9.18B | +9.5% |
| Operating income | $3.51B | $2.67B | $2.66B | +32.3% |
| Net income | $2.38B | $1.82B | $1.43B | +65.9% |
| Diluted EPS | $4.37 | $3.34 | $2.65 | |
| Operating cash flow | $4.00B | $2.19B | $2.28B | +75.5% |
| Capital expenditures | -$513.00M | -$712.00M | -$369.00M | |
| Free cash flow | $3.49B | $1.48B | $1.91B | +82.6% |
| Dividend per share | $2.52 | $2.52 | $2.38 |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Other revenues | $517.00M | $408.00M | +26.7% |
| Product sales | $9.54B | $8.77B | +8.7% |
| Enbrel Sales | $580.00M | $604.00M | -4.0% |
| Product sales growth | 8.73% | 9.08% | |
| Prolia Sales | $759.00M | $1.12B | -32.4% |
| XGEVA Sales | $352.00M | $532.00M | -33.8% |
| Kyprolis Sales | $314.00M | $378.00M | -16.9% |
| BlinCyto Sales | $472.00M | $384.00M | +22.9% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Amgen (AMGN) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/AMGN/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
